This genomic sequencing leader appears to be suffering from multiple revenue headwinds -- at least in the near term.
Here's what it will take for this genomic sequencing company to succeed in 2016.
Despite ongoing volatility in the market, these stocks all climbed. Find out why.
A slower than hoped for launch of the company's new Sequel System is pressuring shares on Monday.
The introduction of a new and cheaper gene sequencing model could give this company an edge.
A double-digit jump on no news.
Investors continue to grow bullish on the company's near term prospects, sending shares to a fresh 52-week high.
The launch of a new sequencing platform gives investors a strong reason to cheer.
Strong growth in tests combined with an increase in reimbursement.
Nothing special here, but nothing bad, either. Look forward to 2016.